OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Call Transcript March 24, 2025
OncoCyte Corporation misses on earnings expectations. Reported EPS is $-1.92791 EPS, expectations were $-0.4.
Gabby Woody: Joining us today are Oncocyte President and CEO, Josh Riggs; Chief Science Officer, Ekke Schutz; and CFO, Andrea James. We also have our analysts with us as panelists. After our prepared remarks, our analysts may ask questions. Attendees may also type questions into the Q&A. Before turning...
